Pregabalin found more effective than pramipexole in restless leg syndrome

mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting

A major multicenter study undertaken in restless leg syndrome (RLS) demonstrated greater efficacy for the alpha-2-delta ligand pregabalin than the dopamine agonist pramipexole, which has been widely regarded until now as the first-line treatment.

In the study, presented at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, United States, 719 patients were randomized to pregabalin 300 mg/day or 1 of 2 dosing arms of pramipexole (0.25 mg/day or 0.5 mg/day) and followed for 52 weeks. Pregabalin was associated with significantly greater improvement in symptoms relative to baseline than placebo or pramipexole, according to measurements made with the International RLS Study Group Rating Scale (IRLS). Moreover, pregabalin produced less of the contradictory augmentation of symptoms that can be associated with...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in mdCurrent Conference Reports, Neurology, Pharmacology, Primary Care and tagged , , , , , , , , . Volume: .